Stichworte
Multiples Myelom ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

306 Suchergebnisse.

Sortieren (Relevanz) ▾

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

- 27.09.18 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ); ODM derived from: https://clinicaltrials.gov/show/NCT00773838

Eligibility Relapsed or Refractory Multiple Myeloma NCT00642954

- 26.09.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074); ODM derived from: https://clinicaltrials.gov/show/NCT00642954

Eligibility Transplantation, Homologous, multiple myeloma and plasma cell leukemia NCT00899847

- 26.09.18 - 1 Formular, 4 Itemgruppen, 22 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Inclusion criteria for donor, Exclusion Criteria, Exclusion criteria for donor
Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG; ODM derived from: https://clinicaltrials.gov/show/NCT00899847

Eligibility Relapsed and/or Refractory Multiple Myeloma NCT00882063

- 26.09.18 - 1 Formular, 2 Itemgruppen, 26 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00882063

Eligibility Refractory Multiple Myeloma NCT00912899

- 25.09.18 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00912899

Eligibility Myeloma NCT00966693

- 09.07.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00966693

Eligibility Multiple Myeloma NCT02467010

- 03.07.18 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance; ODM derived from: https://clinicaltrials.gov/show/NCT02467010

Eligibility Multiple Myeloma NCT01829412

- 03.07.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Exclusion Criteria
Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01829412

Eligibility Multiple Myeloma NCT01314963

- 03.07.18 - 1 Formular, 1 Itemgruppe, 13 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy; ODM derived from: https://clinicaltrials.gov/show/NCT01314963

Eligibility Multiple Myeloma NCT01264315

- 03.07.18 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT01264315

Eligibility Multiple Myeloma NCT01207765

- 03.07.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Fixed Dose Radioimmunotherapy (Zevalin) for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01207765

Eligibility Multiple Myeloma NCT01160107

- 02.07.18 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01160107